Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322323 | 1.00 | ABCG2 (0.34) | ABCG2SPHK1BRD4MMP13MEN1 | |
| SCHEMBL2322328 | 1.00 | ABCG2 (0.34) | ABCG2SPHK1BRD4MMP13MEN1 | |
| SCHEMBL2322318 | 1.00 | ABCG2 (0.34) | ABCG2SPHK1BRD4MMP13MEN1 | |
| SCHEMBL2327384 | 0.94 | ALDH1A1 (0.34) | SPHK1BRD4MMP13MEN1KMT2A | |
| SCHEMBL2327374 | 0.94 | ALDH1A1 (0.34) | SPHK1BRD4MMP13MEN1KMT2A | |
| SCHEMBL2327380 | 0.94 | ALDH1A1 (0.34) | SPHK1BRD4MMP13MEN1KMT2A | |
| SCHEMBL2327377 | 0.94 | ALDH1A1 (0.34) | SPHK1BRD4MMP13MEN1KMT2A | |
| SCHEMBL4974681 | 0.93 | ABCG2 (0.34) | ABCG2MMP13NR1D1 | |
| SCHEMBL4974684 | 0.93 | ABCG2 (0.34) | ABCG2MMP13NR1D1 | |
| SCHEMBL4974691 | 0.93 | ABCG2 (0.34) | ABCG2MMP13NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2074108-B3 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2581366-A1 | Renin Inhibitors | Vitae Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2074108-B1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2081927-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090312369-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS , INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090312369-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS , INC. | 2009-12-17 | — | — | US | disclosed |
| EP-2074108-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008036247-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | ABCG2 1039/4885SPHK1 1780/4885BRD4 2123/4885 |
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | ABCG2 217/4885SPHK1 3345/4885BRD4 2515/4885 |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | ABCG2 1092/4885SPHK1 798/4885BRD4 1079/4885 |
| US-20090312369-A1 | Renin Inhibitors | ACE, REN, DNPEP | ABCG2 1062/4885SPHK1 2172/4885BRD4 2248/4885 |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | ACE, DNPEP, PEPD | ABCG2 1237/4885SPHK1 759/4885BRD4 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.